From Bioreactor to Patient: Scalable Manufacturing and Delivery of Therapeutic Phages
Danish J. Malik, Loughborough University, UK
Therapeutic phages cannot advance clinically without robust, scalable, and regulatory-aligned manufacturing platforms.
This presentation will provide an integrated view of upstream production, downstream purification, formulation science, and respiratory delivery strategies for therapeutic bacteriophages.
Recent data from Prof. Malik’s laboratory will be presented, focusing on process intensification and scalable bioprocess design.
Key Scientific Highlights
Upstream Production
- Phage amplification in stirred-tank bioreactors
- Identification of critical process parameters influencing high-titre yields
- High-throughput scale-down models for upstream optimisation
Downstream Processing
- Scalable depth filtration
- Ultrafiltration platforms
- Chromatographic purification strategies
- Removal of host cell impurities and process contaminants
Formulation Science
- Spray drying for dry powder phage products
- Freeze drying approaches
- Stability considerations for long-term storage
Delivery Strategy
- Nebulization systems for respiratory infections
- Aerosol performance and phage viability considerations
- Translational implications for pulmonary phage therapy
Strategic Relevance for Phage Therapy 2026
- Bridges bioprocess engineering and clinical translation
- Addresses GMP-aligned scalable manufacturing
- Connects formulation science with therapeutic delivery
- Provides practical frameworks for respiratory phage applications
Targeting Phage Therapy 2026
April 9-10, 2026
– Valencia, Spain
www.phagetherapy-site.com